TRU NIAGEN® to be Featured at the American Academy of Anti-Aging Medicine Annual Meeting
December 12 2018 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC) announced today it will feature TRU
NIAGEN® (Booth #6095) at the American Academy of Anti-Aging
Medicine World Congress, a gathering of physicians, researchers,
and healthcare practitioners from Dec. 13-15 in Las Vegas, NV.
Dr. Charles Brenner, ChromaDex Chief Scientific Advisor and the
Roy J. Carver Chair and Head of Biochemistry at the University of
Iowa, will be presenting "How to Hack Your NAD: Scientifically
Validated Strategies for Resisting Stress and Aging Better" at
4:30pm PST on Dec. 13 in the Exhibit Hall, Product Theatre
Stage.
The discussion on NAD and biohacking will continue on Friday,
Dec. 14 from 3:45-4:15pm PST at the TRU NIAGEN® booth—Dave Asprey,
Founder & CEO of Bulletproof, will be signing complimentary
copies of his new book, Game Changers: What Leaders, Innovators,
and Mavericks Do to Win at Life—come early as quantities are
limited.
Members of the TRU NIAGEN team will be on site throughout the
conference to discuss the scientific evidence behind the efficacy
of the novel vitamin B3, as well as the published clinical studies
supporting its benefit in humans. Visitors to the booth will also
receive a complimentary bottle of TRU NIAGEN PRO, a high-dose
version exclusively for sale through healthcare providers.
For additional information on the science supporting TRU NIAGEN
PRO visit practitioner.truniagen.com.
About TRU NIAGEN®:TRU NIAGEN® is a branded
dietary supplement brought to market by key nicotinamide riboside
innovator and patent holder, ChromaDex. NIAGEN® nicotinamide
riboside (NR), also supplied by ChromaDex, is the sole active
ingredient in TRU NIAGEN®. Multiple clinical trials demonstrate
NIAGEN® is proven to boost NAD (nicotinamide adenine dinucleotide)
levels, which decline with age. Only NIAGEN® has twice been
successfully reviewed under FDA's new dietary ingredient (“NDI”)
notification program, and has also been successfully notified to
the FDA as generally recognized as safe (“GRAS”).
About ChromaDex:ChromaDex Corp.
is an integrated, global nutraceutical company devoted to improving
the way people age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD and identify and develop novel, science-based
ingredients. Its flagship ingredient, NIAGEN® nicotinamide
riboside, sold directly to consumers as TRU NIAGEN®, is backed with
clinical and scientific research, as well as extensive IP
protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex
maintains a website at www.chromadex.com to which ChromaDex
regularly posts copies of its press releases as well as additional
and financial information about the Company.
Forward-Looking Statements:This
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities and Exchange Act of 1934, as amended.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 30, 2017, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof. ChromaDex provided research materials and a portion of
the grant funding as a collaborator for the study.
ChromaDex Media Contact:Alex Worsham, Director
of Strategic Partnerships949-648-3775alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Sr. Director of FP&A and Investor
Relations949-344-3782briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Sep 2023 to Sep 2024